Diego Bagnasco
Overview
Explore the profile of Diego Bagnasco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1066
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bagnasco D, Bondi B, Brussino L, Nicola S, Cameli P, Tiotiu A, et al.
J Pers Med
. 2025 Feb;
15(2).
PMID: 39997320
: Severe allergic asthma is usually treated with omalizumab; however, this drug may not be effective for every patient. By its action, dupilumab could be an alternative in these patients....
2.
Caminati M, Maule M, Bagnasco D, Beghe B, Braido F, Brussino L, et al.
J Allergy Clin Immunol Pract
. 2025 Feb;
PMID: 39956163
Background: A transient and usually asymptomatic increase in blood eosinophil count (BEC) associated with dupilumab treatment has been described. Predicting factors related to the increase in BEC and the occurrence...
3.
Bertolini M, Buono F, Galli A, Bagnasco D, Guastini L, Feltri M, et al.
Eur Arch Otorhinolaryngol
. 2025 Jan;
PMID: 39798025
Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a complex systemic fibroinflammatory condition with different clinical manifestations affecting multiple organ systems. Despite its rarity, the disease presents diagnostic and therapeutic challenges due...
4.
Cosini F, Bagnasco D, Braido F, Canonica G, Passalacqua G, Testino E, et al.
Respir Med
. 2025 Jan;
237:107944.
PMID: 39761733
Background: Global Initiative for Asthma (GINA) recently recommends clinicians to reduce inhaled corticosteroid doses in patients with severe asthma who respond positively to monoclonal antibodies (MAbs). Objective: As we operated...
5.
Trave I, Salvi I, Bagnasco D, Parodi A, Cozzani E
Acta Derm Venereol
. 2024 Sep;
104:adv40800.
PMID: 39295583
No abstract available.
6.
Costanzo G, Caruso C, Paoletti G, Baglivo I, Colantuono S, Bagnasco D, et al.
J Pers Med
. 2024 Aug;
14(8).
PMID: 39202045
Randomized controlled trials have demonstrated responses to clinical parameters, but a significant proportion of allergy patients in real-life settings would have been excluded from such studies. Therefore, real-world research is...
7.
Canonica G, Bagnasco D, Bondi B, Varricchi G, Paoletti G, Blasi F, et al.
J Asthma
. 2024 Jul;
61(12):1593-1600.
PMID: 38984764
In the field of severe asthma, the concept of disease control has recently been integrated by the one of clinical remission. With this new concept, we move on to analyze...
8.
Bagnasco D, De Ferrari L, Bondi B, Candeliere M, Mincarini M, Riccio A, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892164
Thymic stromal lymphopoietin (TSLP), is a protein belonging to a class of epithelial cytokines commonly called alarmins, which also includes IL-25 and IL-33. Functionally, TSLP is a key player in...
9.
Pini L, Bagnasco D, Beghe B, Braido F, Cameli P, Caminati M, et al.
J Clin Med
. 2024 May;
13(10).
PMID: 38792553
Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. This retrospective multicentric study...
10.
Bagnasco D, Bondi B, Caminati M, Nicola S, Pini L, Milanese M, et al.
Biomedicines
. 2024 May;
12(5).
PMID: 38790922
Background: In its severe form, where possible, asthma is treated using biological drugs in order to reduce, as much as possible, the use of systemic steroids. Mepolizumab is effective for...